[Pterygium. Etiology, clinical aspects and novel adjuvant therapies]

Ophthalmologe. 2010 Jun;107(6):517-20, 522-4. doi: 10.1007/s00347-009-2100-4.
[Article in German]

Abstract

Pterygium is a common UV-induced degeneration of the limbal conjunctiva. Indications for surgery include loss of visual acuity, increasing astigmatism, impending invasion of the optical axis and ocular surface discomfort. Measures to reduce the risk of recurrence include 1. an optimal surgical strategy (intra-operative use of antimetabolites and free conjunctival graft), 2. postoperative topical therapy with steroids and lubricants free of preservatives and 3. long-term UV protection. Novel anti-angiogenic treatment approaches for prevention of recurrence of pterygium are discussed.

Publication types

  • English Abstract

MeSH terms

  • Adrenal Cortex Hormones / administration & dosage
  • Alkylating Agents / administration & dosage
  • Angiogenesis Inhibitors / administration & dosage
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Combined Modality Therapy
  • Conjunctiva / pathology
  • Conjunctiva / radiation effects
  • Conjunctiva / transplantation
  • Diagnosis, Differential
  • Eye / radiation effects*
  • Eye Protective Devices
  • Humans
  • Mitomycin / administration & dosage
  • Pterygium / etiology*
  • Pterygium / pathology
  • Pterygium / therapy
  • Radiation Injuries / diagnosis*
  • Radiation Injuries / pathology
  • Radiation Injuries / therapy
  • Secondary Prevention
  • Ultraviolet Rays / adverse effects*

Substances

  • Adrenal Cortex Hormones
  • Alkylating Agents
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Mitomycin